Tag Archives: Industry Analysis

Biotech Sector Performance Update 1H 2010

In my last update back in April, the broadest Biotech index (the 125 company Nasdaq Biotech Index, NBI) was up 11% for the year and ahead of just about every major sector. One quarter later things look a little different. The NBI is now down 5% and trailing 4 of the 10 S&P sectors (chart 1): However, the spotlight continues to shine on the AMEX Biotech Index (BTK). The BTK is up 8.6% for the Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , ,

2010 BIO Business Forum Partnering Results

2010 BIO Business Forum in Chicago was a huge success last week. We hit record numbers for the three day event making this the single largest partnering event ever held. Our updated 1×1 partnering software system received over 107,000 requests for meetings that resulted in over 17,000 meetings. To put that in perspective, 10 years ago there were only 300 meetings, yielding an explosive 43% CAGR for partnering at the BIO International Convention.  The meetings were set up by some 2,100 Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

1Q 2010 – All Time High for the BTK

The first quarter of 2010 saw the Amex Biotech Index (BTK) hit another all time high, thanks largely to Intermune’s (ITMN) jump of 240% and OSI’s (OSIP) gain of 92%. (Intermune received a positive recommendation from an FDA panel for pirfenidone, and OSI’s stock moved on the $3.5B hostile bid from Astellas.) The Nasdaq Biotech Index (NBI) climbed to its highest in over eight years. Both of these biotech indices are up since the financial Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

FOPO – A Late Stage Financing Tool

The follow-on public offering (FOPO) market has been strong for biotech since early last year, but has it been open to companies at all stages of drug R&D? It turns out that FOPOs have been utilized primarily by late-stage biotechs.  I recently took a look at FOPOs listed in the Windhover Strategic Transactions database that took place from January 2009 to March 2010. Of the 46 drug development companies that raised over $25M in a Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: ,

Is P/E Compression Making Biotech a Bargin?

For the first time in biotech history, price to earnings multiples (P/E based on next year’s projected EPS) for large cap biotechs dropped below the average P/E for the S&P 500 index. Is this a sign that biotech is cheap relative to the market or is it because earnings growth is shrinking, commanding a lower P/E ratio? If we look at end of quarter P/E ratios (price /next 12 months of earnings) for the largest biotech Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,